Showcasing Its Pandemic Response Drug Discovery, Berkeley Lights Prepares For IPO
'Nanofludics' Accelerates Antibody Discovery
Executive Summary
Chief executive Eric Hobbs talks about the technology needed to accelerate antibody, cell therapy and synthetic biology, and prepare for the next pandemic.
You may also be interested in...
IPO Update: High-Flying Biopharma IPOs Average 77.1% Return Through Q2
The performance of 29 biopharma firms that launched IPOs during the first half of 2020 is staggering compared with 28 drug developers that went public in the first half of 2019 with a 10% average return.
How Significant Will Veklury’s Sales Be? Forecasts Show It Is Hard To Tell
Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.
Is Biogen’s Aducanumab Approvable? Opinions Divided Ahead Of Review
Many clinicians doubt that aducanumab can really help slow the decline in Alzheimer’s patients – but US FDA could offer it the benefit of the doubt.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports